Bioextrax AB (SE:BIOEX)

:BIOEX

BIOEX

Bioextrax AB

RESEARCH TOOLSreports

Want to see SE:BIOEX full AI Analyst Report?

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr124.72M

Enterprise Valuekr103.57M

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.91

Next Earnings

May 14, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding47,601,730

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr5.34M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces refinancing and interest-rate risk, giving management meaningful financial flexibility during multi-year R&D and commercialization cycles typical in industrial biotech. This lowers the immediate need for costly financing, supporting project continuity and partnership negotiations over the next 2–6 months.

Industrial Biotech / Biorefinery FocusA focus on converting renewable raw materials and industrial side streams into higher-value bioactive compounds aligns with long-term structural trends: circular economy, demand for sustainable ingredients, and industrial decarbonization. These secular drivers support persistent market opportunity and partner interest beyond short-term cycles.

Multiple Commercial PathwaysHaving product sales, licensing and fee-for-service R&D provides diversified monetization routes, reducing reliance on a single revenue source. This business-model flexibility allows the company to pursue partnerships, milestone deals, or contract work while scaling manufacturing, improving resilience during early commercialization phases.

Bears Say

Negative Gross Profit PersistencyNegative gross profit indicates the core process economics are not yet commercially viable at current scale. Unless unit costs fall or realized pricing improves, persistent negative gross margins will continue to consume capital, hinder margin sustainability, and limit the company’s ability to scale or invest in commercialization over the coming months.

Consistent Operating Cash BurnContinuous negative operating and free cash flow, with accelerating cash burn in 2025, raises the likelihood of near-term external funding needs. This constrains strategic choices, may force dilution or funding on unfavorable terms, and risks delaying commercialization milestones if additional capital is not secured.

Shrinking Equity BaseDeclining equity reflects cumulative losses and erodes the company’s buffer to absorb further operating deficits. Even with no debt, a shrinking capital base weakens financial resilience, reduces optionality for investment, and increases dependence on external capital which could be dilutive or restrictive for growth initiatives.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

2M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr124.72M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is May 14, 2026 which is in 15 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Feb 19, 2026. The company reported -kr0.11 earnings per share for the quarter, missing the consensus estimate of kr0 by -kr0.11.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.1.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 47,601,730 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.11 in its last earnings report, missing expectations of kr0. Following the earnings report the stock price went up 5.98%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based materials and waste management, offering innovative solutions for the production of bioplastics, animal feed, and other materials using its proprietary microbial processes.